BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23102611)

  • 1. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.
    Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T
    Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
    Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
    Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).
    Vogelmeier CF; Asijee GM; Kupas K; Beeh KM
    Adv Ther; 2015 Jun; 32(6):537-47. PubMed ID: 26100349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
    Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
    Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
    Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
    Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
    Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
    Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
    Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
    Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
    Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.
    Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S
    COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.
    Fukuchi Y; Fernandez L; Kuo HP; Mahayiddin A; Celli B; Decramer M; Kesten S; Liu D; Tashkin D
    Respirology; 2011 Jul; 16(5):825-35. PubMed ID: 21539680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early treatment of COPD with tiotropium].
    Buhl R; Welte T; Vogelmeier C; Gillissen A; Voshaar T; Kögler H; Liu D; Glaab T
    Pneumologie; 2012 Oct; 66(10):589-95. PubMed ID: 23011771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.
    Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N
    Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P; Wencker M; Glaab T; Vogelmeier C
    Am J Respir Crit Care Med; 2007 Jan; 175(2):144-9. PubMed ID: 17053207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
    Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
    Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.